Monoclonal antibody therapy improves survival in cancer-associated hyper-inflammatory disorder
Adult patients with newly diagnosed malignancy-associated hemophagocytic lymphohistiocytosis (mHLH) – a rare, aggressive hyperinflammatory condition – who were treated with the first-in-class monoclonal antibody, ELA026, experienced a 100% response rate and an improved survival rate at two months, according to researchers from The University of Texas MD Anderson Cancer Center. Findings suggest that early intervention with ELA026 may provide meaningful clinical benefits for patients with few options. “It is common for patients with mHLH...